Answers are grounded in this paper and cite their sources.
Introduction Ocular chemical injuries are vision-threatening emergencies that demand immediate, systematic, and phase-specific management. Early intervention, particularly through copious irrigation, is critical to limit progressive tissue damage and preserve vision.Areas covered Acute-phase care focuses on controlling inflammation, preventing epithelial and stromal breakdown, and supporting re-epithelialization. Nonetheless, long-term complications such as limbal stem cell deficiency, corneal scarring, neovascularization, and secondary glaucoma frequently occur. Emerging therapeutics including stem cell–based therapies, nanotechnology-based drug delivery, and anti-angiogenic agents show promise for improving outcomes. Optimal outcomes depend on a multidisciplinary approach integrating corneal, glaucoma, and oculoplastic expertise.Expert opinion Management of severe ocular chemical injury remains challenging, with unmet needs in both cell replacement and inflammation control. Approaches such as allo-SLET, mucosal grafting, MSCs, and iPSC-derived epithelial cells, show promise for restoring the limbal stem cell niche and improving outcomes advanced disease.
No takes yet. Share an insight, caveat, or question.
Yucel et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: